该论文来源于网络，本站转载的论文均是优质论文，供学习和研究使用，文中立场与本网站无关，版权和著作权归原作者所有，如有不愿意被转载的情况，请通知我们删除已转载的信息，如果需要分享，请保留本段说明。 [摘要] 目的 探讨孟鲁司特钠联合布地奈德治疗治疗支气管哮喘的临床疗效。 方法 研究对象选取呼吸内科2016年3月～2017年3月治疗的支气管哮喘（Ba）患者98例，根据不同治疗方法，分为研究组与对照组，对照组仅给予布地奈德进行治疗，研究组在前者基础上，联合孟鲁司特钠实施治疗，观察两组的治疗效果并进行对比。结果 （1）治疗后，%，%，差异有统计学意义（P<）;（2）研究组的 PEF%、FEV1等肺功能指标值显著优于对照组（P<）;（3）研究组与对照组的不良反应发生情况，差异无统计学意义（P>）。 结论 孟鲁司特钠联合与布地奈德治疗Ba疗效佳，能显著改善患者气道受限，提高其生活质量，值得推广。 [关键词] 布地奈德;孟鲁司特钠;白三烯;支气管哮喘 [中图分类号] [文献标识码] B [文章编号] 1673-9701（2019）09-0096-02 [Abstract] Objective To investigate the clinical efficacy of montelukast sodium combined with budesonide in the treatment of bronchial asthma. Methods 98 patients with Ba（bronchial asthma） who were treated in the department of respiratory medicine from March 2016 to March 2017 were enrolled in the study. According to different treatment methods， they were divided into study group and reference group. The reference group was only given budesonide for treatment. On the basis of the former， the study group was treated with montelukast sodium. And the therapeutic effects of the two groups were observed and compared. Results （1）After treatment， the total effective rate of the study group was %， while the total effective rate of the reference group was %， the difference was statistically significant（P<）; （2）The study group's PEF%， FEV1 and other lung function indicators were significantly better than those of the reference group（P<）; （3）There was no statistical significance in the adverse reactions betwen the study group and the reference group（P>）. Conclusion The montelukast sodium combined with budesonide in the treatment of Ba has good efficacy， which can significantly improve the airway limitation of patients and improve their life quality， and is worth promoting. [Key words] Budesonide;Montelukast sodium;Leukotriene;Bronchial ast
